148 related articles for article (PubMed ID: 38534948)
1. Biomarker Turnaround Times and Impact on Treatment Decisions in Patients with Advanced Non-Small Cell Lung Carcinoma at a Large Canadian Community Hospital with an Affiliated Regional Cancer Centre.
Fleming KE; Hupel A; Mithoowani H; Lulic-Kuryllo T; Valdes M
Curr Oncol; 2024 Mar; 31(3):1515-1528. PubMed ID: 38534948
[No Abstract] [Full Text] [Related]
2. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer.
Lim C; Tsao MS; Le LW; Shepherd FA; Feld R; Burkes RL; Liu G; Kamel-Reid S; Hwang D; Tanguay J; da Cunha Santos G; Leighl NB
Ann Oncol; 2015 Jul; 26(7):1415-21. PubMed ID: 25922063
[TBL] [Abstract][Full Text] [Related]
3. Referred molecular testing as a barrier to optimal treatment decision making in metastatic non-small cell lung cancer: Experience at a tertiary academic institution in Canada.
Grafham GK; Craddock KJ; Huang WY; Louie AV; Zhang L; Hwang DM; Parmar A
Cancer Med; 2024 Feb; 13(3):e6886. PubMed ID: 38317584
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
Front Immunol; 2020; 11():1173. PubMed ID: 32587591
[No Abstract] [Full Text] [Related]
5. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
Redman MW; Papadimitrakopoulou VA; Minichiello K; Hirsch FR; Mack PC; Schwartz LH; Vokes E; Ramalingam S; Leighl N; Bradley J; Miao J; Moon J; Highleyman L; Miwa C; LeBlanc ML; Malik S; Miller VA; Sigal EV; Adam S; Wholley D; Sigman C; Smolich B; Blanke CD; Kelly K; Gandara DR; Herbst RS
Lancet Oncol; 2020 Dec; 21(12):1589-1601. PubMed ID: 33125909
[TBL] [Abstract][Full Text] [Related]
6. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network.
Robert NJ; Espirito JL; Chen L; Nwokeji E; Karhade M; Evangelist M; Spira A; Neubauer M; Bullock S; Walberg J; Cheng SK; Coleman RL
Lung Cancer; 2022 Apr; 166():197-204. PubMed ID: 35313244
[TBL] [Abstract][Full Text] [Related]
7. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
8. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
9. Impact of Reflex EGFR/ ALK Testing on Time to Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Cheema PK; Menjak IB; Winterton-Perks Z; Raphael S; Cheng SY; Verma S; Muinuddin A; Freedman R; Toor N; Perera J; Anaka M; Victor JC
J Oncol Pract; 2017 Feb; 13(2):e130-e138. PubMed ID: 28029301
[TBL] [Abstract][Full Text] [Related]
10. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
11. Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study.
Lee DH; Tsao MS; Kambartel KO; Isobe H; Huang MS; Barrios CH; Khattak A; de Marinis F; Kothari S; Arunachalam A; Cao X; Burke T; Valladares A; de Castro J
PLoS One; 2018; 13(8):e0202865. PubMed ID: 30148862
[TBL] [Abstract][Full Text] [Related]
12. Signaling protein signature predicts clinical outcome of non-small-cell lung cancer.
Jin BF; Yang F; Ying XM; Gong L; Hu SF; Zhao Q; Liao YD; Chen KZ; Li T; Tai YH; Cao Y; Li X; Huang Y; Zhan XY; Qin XH; Wu J; Chen S; Guo SS; Zhang YC; Chen J; Shen DH; Sun KK; Chen L; Li WH; Li AL; Wang N; Xia Q; Wang J; Zhou T
BMC Cancer; 2018 Mar; 18(1):259. PubMed ID: 29510676
[TBL] [Abstract][Full Text] [Related]
13. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in
Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728
[TBL] [Abstract][Full Text] [Related]
14. Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer.
Huang D; Zhang F; Tao H; Zhang S; Ma J; Wang J; Liu Z; Cui P; Chen S; Huang Z; Wu Z; Zhao L; Hu Y
Target Oncol; 2020 Feb; 15(1):93-100. PubMed ID: 32052340
[TBL] [Abstract][Full Text] [Related]
15. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.
Aguilar EJ; Ricciuti B; Gainor JF; Kehl KL; Kravets S; Dahlberg S; Nishino M; Sholl LM; Adeni A; Subegdjo S; Khosrowjerdi S; Peterson RM; Digumarthy S; Liu C; Sauter J; Rizvi H; Arbour KC; Carter BW; Heymach JV; Altan M; Hellmann MD; Awad MM
Ann Oncol; 2019 Oct; 30(10):1653-1659. PubMed ID: 31435660
[TBL] [Abstract][Full Text] [Related]
16. A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.
Kerr KM; Thunnissen E; Dafni U; Finn SP; Bubendorf L; Soltermann A; Verbeken E; Biernat W; Warth A; Marchetti A; Speel EM; Pokharel S; Quinn AM; Monkhorst K; Navarro A; Madsen LB; Radonic T; Wilson J; De Luca G; Gray SG; Cheney R; Savic S; Martorell M; Muley T; Baas P; Meldgaard P; Blackhall F; Dingemans AM; Dziadziuszko R; Vansteenkiste J; Weder W; Polydoropoulou V; Geiger T; Kammler R; Peters S; Stahel R;
Lung Cancer; 2019 May; 131():95-103. PubMed ID: 31027705
[TBL] [Abstract][Full Text] [Related]
17. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
18. Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study.
de Castro J; Tagliaferri P; de Lima VCC; Ng S; Thomas M; Arunachalam A; Cao X; Kothari S; Burke T; Myeong H; Grattan A; Lee DH
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28748556
[TBL] [Abstract][Full Text] [Related]
19. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
20. Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC.
Doroshow DB; Wei W; Gupta S; Zugazagoitia J; Robbins C; Adamson B; Rimm DL
J Thorac Oncol; 2021 Dec; 16(12):2139-2143. PubMed ID: 34455068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
